Key Takeaways
- • Forbion participated in a €2.3B landmark fundraise as part of a broad investor syndicate backing cAMPfield Therapeutics, a newly launched immunology and inflammation-focused biotech.
- • cAMPfield Therapeutics raised $180M in Series A funding led by a syndicate including Novo Holdings, RA Capital Management, Frazier Life Sciences, Forbion, Abingworth, and Venrock.
- • The capital will be deployed to in-license and advance multiple immunology and inflammation therapeutic candidates, positioning cAMPfield as an acquisition-focused platform company.
- • The fundraise represents one of the largest biotech financing rounds tracked in the week of May 18–24, 2026, significantly outpacing concurrent private financings in the sector.
Summary
Forbion Capital Partners participated as a cornerstone investor in cAMPfield Therapeutics' $180M Series A funding round, part of what sources describe as a landmark capital deployment in the European and global biotech space. cAMPfield emerged from stealth in May 2026 as a California-based immunology and inflammation-focused biotech company led by CEO Bill Gerhart, with a business model centered on acquiring and advancing in-licensed therapeutic assets rather than developing proprietary discovery programs.
The Series A syndicate assembled for the financing reflects institutional confidence in the acquisition-led strategy and spans six major life sciences investors: Novo Holdings, RA Capital Management, Frazier Life Sciences, Forbion, Abingworth, and Venrock. This diverse group of experienced biotech investors signals strong backing across both European and U.S.-based capital sources. The $180M raise positioned cAMPfield as the largest private biotech financing tracked during the week of May 18–24, 2026, substantially outpacing other concurrent Series A and growth-stage rounds in the market.
Capital from the Series A will be allocated to in-licensing immunology and inflammation candidates and advancing them through clinical development, a strategy increasingly popular among biotech investors seeking to derisk drug discovery through acquisition of earlier-stage programs rather than reliance on internal R&D. Forbion's participation underscores the firm's continued focus on European and global biotech investments with therapeutic depth in immunology and inflammatory disease areas.
The Series A syndicate assembled for the financing reflects institutional confidence in the acquisition-led strategy and spans six major life sciences investors: Novo Holdings, RA Capital Management, Frazier Life Sciences, Forbion, Abingworth, and Venrock. This diverse group of experienced biotech investors signals strong backing across both European and U.S.-based capital sources. The $180M raise positioned cAMPfield as the largest private biotech financing tracked during the week of May 18–24, 2026, substantially outpacing other concurrent Series A and growth-stage rounds in the market.
Capital from the Series A will be allocated to in-licensing immunology and inflammation candidates and advancing them through clinical development, a strategy increasingly popular among biotech investors seeking to derisk drug discovery through acquisition of earlier-stage programs rather than reliance on internal R&D. Forbion's participation underscores the firm's continued focus on European and global biotech investments with therapeutic depth in immunology and inflammatory disease areas.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.